Document is current
Any future updates will be listed below
-
Authors
Smith, Melanie H. https://orcid.org/0000-0003-2464-8429
Gao, Vianne R.
Periyakoil, Preethi K. https://orcid.org/0000-0001-7923-5571
Kochen, Alejandro
DiCarlo, Edward F.
Goodman, Susan M. https://orcid.org/0000-0003-1197-7864
Norman, Thomas M. https://orcid.org/0000-0002-3755-4379
Donlin, Laura T. https://orcid.org/0000-0002-1428-090X
Leslie, Christina S. https://orcid.org/0000-0002-4571-5910
Rudensky, Alexander Y. https://orcid.org/0000-0003-1280-2898
- License Information
-
More Information
Article History
Received: 26 February 2022
Accepted: 4 May 2023
First Online: 5 June 2023
Competing interests
: A.Y.R. is an SAB member and has equity in Sonoma Biotherapeutics, Santa Ana Bio, RAPT Therapeutics and Vedanta Biosciences. He is an SEB member of Amgen and BioInvent and is a co-inventor or has IP licensed to Takeda that is unrelated to the content of the present study. S.M.G. consults for UCB and has research support from Novartis both of which are unrelated to the present study. The remaining authors declare no competing interests.
